There are separate parts to the bill
Of six online weight-care services sampled in September 2026, five billed separately for medicine and charged a membership fee each month. Some offered a lower first-month price.
These examples concern weight care, not injury recovery. Ask the recovery service you are considering whether it charges these kinds of fees.
Questions for a complete quote
Assessment
A visit fee or an ongoing membership?
Medicine
Included in that fee or billed separately?
Testing
Included, billed separately or paid through insurance?
Ask about shipping, added items, follow-up and cancellation terms too. Put each answer on the same quote.
Weight-medicine prices are examples, not a recovery quote
For weight and diabetes medicines, most drug-maker cash offers fell between $149 and $499 per month as of September 2026.
The product, strength and refill timing affected the price. Some lower-price Zepbound cash offers, for example, put the refill deadline at 45 days after the preceding delivery. A “month” could mean 28 days or one medicine box or tablet bottle, depending on the offer.
Ask how many days your quoted supply covers and what refill deadline keeps that price.
Those figures describe medicine prices paid outside insurance. They are not a total for an athletic recovery programme.
An insurance price is a different kind of price
An insured copay is your share of a covered bill. It is different from the maker’s published list price or a cash offer.
Appetite and blood sugar respond to a signal in the body called GLP-1. Some weight and diabetes medicines copy it.
Medicare’s temporary GLP-1 Bridge gave eligible people access to certain weight medicines in September 2026, with the copay set at $50 monthly. It was not a general price for all peptide care.
Ask the plan which of its rules apply to your prescription before comparing that payment with a cash offer.
Check what changes later
For several maker cash offers and savings cards, the terms ran only through December 31, 2026. Check the price again at that point rather than assuming what the next price will be.